

Tel: 888.999.1371 or 858.642.2058

Fax: 858.642.2046

Web: www.ebioscience.com E-mail: info@ebioscience.com

Product Information

Contents: Polyclonal rabbit anti-mouse CXCL13 (BLC, BCA-1)

Catalog Number: 14-7989

Sizes: 50 ug, 200 ug

Formulation: Contains 0.09% NaN₃.

The 50µg size of this antibody is supplied in liquid form. The 200µg size of this antibody may be supplied in liquid or lyophilized powder

forms. To reconstitute the lyophilized antibody, add 200µl of PBS for a final concentration of 1mg/ml.

Storage Conditions: Store at 4°C. Avoid repeated freeze/thaw cycles.

Clone: Polyclonal Isotype: Rabbit IgG

Available Formats of This Product				
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
14-7989	Polyclonal anti-mouse CXCL13 (BLC, BCA-1)	N/A	N/A	WB

Description

The BCA-1 polyclonal antibody reacts with mouse BCA-1 (CXCL13). The antibody was generated using *E. coli*-expressed mouse CXCL13 as an immunogen. CXCL13, or BLC (B-lymphocyte chemoattractant, mouse equivalent of human B cell-attracting chemokine-1, BCA-1), is a 12 kDa recently-characterized ELR-CXC chemokine. CXCL13 shows high levels of expression in the spleen, Peyer's patches, and mesenteric lymph nodes. It is reported to be the ligand for CXCR5. It attracts primarily B cells *in vitro*. Cell lines transfected with CXCR5 demonstrate both chemotaxis and calcium flux in response to CXCL13. Cross-reactivity of this polyclonal to BLC in other species has not been determined

Usage

For research use only, not for diagnostic or therapeutic use. This polyclonal antibody has been reported for use in immunoblotting (WB).

Applications Tested

The tested titer for Western blot is 1:5000. It is recommended that the reagent be carefully titrated for optimal performance in the assay of interest.

References

Gunn M, et al. 1998. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391:799-803. Legler D, et al. 1998. B cell attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 187(4):655-660.